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Determinants of Clinician Adoption of Regenerative Therapies in the UK and 1 
Canada: An Ophthalmology Perspective 2 
 3 
1. Summary 4 
 5 
The determinants of adoption of regenerative medicine therapies are currently poorly 6 
understood. This study aims to draw comparison between the UK and Canada in terms of factors 7 
likely to affect healthcare adoption of future regenerative therapies in ophthalmology. Conducting 8 
semi-structured interviews with senior ophthalmologists in the UK and Canada, their perceptions 9 
of factors either enabling or limiting adoption were recorded and analysed.  A number of key 10 
concepts were extracted from the interview data which were perceived by stakeholders to 11 
contribute to adoption. The core factors developed in this work will be of use to those looking to 12 
understand the opportunities and risks involved in securing clinician adoption in both the UK and 13 
Canada. 14 
2. Keywords 15 
Adoption, Reimbursement, UK, NHS, Canada, Ophthalmology, Translation 16 
 17 
 18 
3. Article 19 
3.1 Introduction 20 
Adoption of regenerative medicine (RM) therapies is relatively unchartered territory, with 21 
few approved demonstrators having secured reimbursement. In ophthalmology there are a 22 
variety of indications in which RM and more specifically cell therapy would offer very real 23 
benefit [1,2]. However, for these benefits to be realised, therapy developers must 24 
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understand the drivers and potential determinants of uptake into healthcare. This will be 25 
critical to the development of the industry sector and core both to affording widespread 26 
patient access to these therapies, and in realising national economic benefit from attracting 27 
industry investment [3].  28 
Healthcare markets around the world vary significantly in the way that healthcare is 29 
financed and delivered. Both the UK’s National Health Service (NHS) and Canada’s Medicare 30 
are well appreciated examples of “single-payer” healthcare systems in which healthcare is 31 
funded through taxation, and delivered through publicly governed providers [4]. The NHS 32 
has been characterised as a slow adopter of medical technologies, described to be behind 33 
many other countries in terms of the therapies it provides [5–7].  34 
To understand if the market characteristics of the NHS are a consequence of its operation as 35 
a single-payer system, this work has attempted to draw comparisons with Canada. Canada 36 
has received more attention in recent years for its long waiting lists for elective surgeries 37 
and high prices paid for patented pharmaceuticals [8,9]. Both the UK and Canada are world 38 
leaders in the basic research of RM, with both countries’ governments keen to gain 39 
economic benefit from commercially exploiting this exciting area of technology [10,11] 40 
Ophthalmology has been a target area of particular interest to therapy developers for 41 
several reasons. The eye is a small, enclosed, largely immune-privileged organ, which allows 42 
relatively easy surgical access [12,13]. Transplant sites can be easily visualized on account of 43 
the organs transparency and functional responses to interventions in many cases can be 44 
measured non-invasively with confidence [14].  In addition,  effective therapeutic doses of 45 
cells in ocular clinical indications are likely to be significantly lower than in other disease 46 
areas such as cardiac applications or diabetes [15]. The market opportunities for some 47 
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clinical indications in this space are also significant and for commercial developers could 48 
offer a “blockbuster” target [16]. For these reasons it is unsurprising that some of the first 49 
clinical trials involving the use of cells derived from embryonic stem cells [17] and induced 50 
pluripotent stem cells [18] have been in this clinical area. 51 
This work aims to qualitatively compare the factors affecting or likely to affect the 52 
translation, early use and system-wide adoption of RM therapies in both the UK and 53 
Canada. The term regenerative medicine has been used throughout to describe advanced 54 
medicinal therapies based on gene therapy, cellular therapeutics and tissue engineering 55 
[10]. 56 
3.2 Methods 57 
This study used a qualitative design based on “problem-centered interviews” (PCI) [19]. The 58 
data collection phase ran from Jan 2013 to Sept 2013. 22 consultant ophthalmologists with 59 
links to RM research programmes were contacted in both the UK and Canada. Respondents 60 
were interviewed face-to-face and in cases when this was not possible by telephone. 34 61 
candidates were invited for interview in the UK. 44 candidates were invited in Canada to 62 
reach an equal number of participants in both territories (11 participants).   63 
3.2.1 Data Collection 64 
An interview framework was developed using results from an unpublished literature review 65 
conducted at the start of this work. The interview framework was trialled on a small number 66 
of ophthalmologist volunteers, to ensure no areas of questioning were ambiguous or 67 
misleading. The 22 PCI lasted on 40 minutes on average and were recorded using an audio 68 
recorder.  69 
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3.2.2 Data Processing 70 
PCI recordings were transcribed verbatim from voice recordings producing 22 transcripts. 71 
Transcripts were interpreted by using the method of qualitative content analysis as 72 
described by Mayring [20]. In brief, interview transcripts were analysed together with the 73 
audio recording. A first pass of transcripts showed that participants’ responses in PCI could 74 
be grounded in one of three potential phases relating to the use RM therapies in healthcare. 75 
These were Translation; Early Use and System-wide Adoption. Controlled interpretation was 76 
then applied to the categorized passages, paraphrasing and classifying with a code 77 
corresponding to a sub-theme. Interview transcripts were then compared with one another 78 
to further group sub-themes into descriptive factors, deemed important at a particular 79 
stage of the development process. A final controlling phase was performed to ensure that 80 
thematic categorization was justified and consistent between entire samples for both UK 81 
and Canadian participants. A semi-quantitative analysis of coded data was then carried out 82 
allowing a comparison of responses from UK and Canadian participants. This involved 83 
recording the frequency at which sub-theme codes were presented in each of the interviews 84 
referred to as the grounded value [21]. In addition, the most recurrent codes with the 85 
highest grounded values were broken down as either being a “barrier” or an “enabler” to 86 
RM adoption, in accordance to the context in which the respondent gave evidence.  87 
 88 
3.3 Results and Discussion 89 
 90 
Participants were approached both in Canada and the UK. Response rates were higher in the 91 
UK relative to Canada (Table 1).  The UK sample covered clinicians working in a variety of 92 
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regions. The Canadian sample importantly covered clinicians from Alberta and British 93 
Columbia (BC); and Ontario. Higher response rates in the UK may have been on account of 94 
the familiarity of the UK participants with the authors’ research group and institutions. The 95 
final 22 respondent convenience sample of ophthalmologists was drawn from those who 96 
had links to RM research programmes and naturally came from a number of institutions and 97 
regions. As might be expected there were differences in the responses given across the 98 
sample which appeared to be predicated on the types of institutions within which these 99 
ophthalmologists practiced. In general, respondents working for high profile research 100 
centres appeared to look favourably on the systems and processes which supported the 101 
adoption of new therapies. On the other hand, clinicians coming from smaller centres gave 102 
evidence that they were frustrated with the pace of change, the bureaucracy and the 103 
amount of justification required to adopt a therapy, which had been used effectively 104 
elsewhere. 105 
 106 
3.3.1 Stages of Adoption of Regenerative Medicine in Ophthalmology 107 
An area of common discussion throughout the interview process was where in the therapy 108 
development pathway participants responses were focussed. The transition of a therapy 109 
through research and development, clinical trials and into mainstream clinical use of course 110 
is not linear. Clinicians in both countries had significantly different understandings of how 111 
their institutions supported clinical research and managed the processes of clinical adoption 112 
(Figure 1).  113 
The respondent sample described three potential phases in which they could engage with 114 
an RM therapy. The first, prior to market authorisation involves the clinical translation of a 115 
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therapy in which a clinician decides to engage in use under the constraints research 116 
protocols. The sample described a second potential phase of early use after a therapy had 117 
gained market approval, or after being verified under hospital exemption or a “specials” 118 
licence in the UK [22]. During this phase, therapies with low levels of evidence supporting 119 
their effectiveness could be used by clinicians but were not supported as the first-line 120 
treatment and often not formally reimbursed. In general respondents saw this as a means 121 
to offer these therapies on a named-patient basis or to small patient numbers. System-wide 122 
adoption of new therapies could occur only after suitable assessments of the therapies 123 
value to the health system have been carried out. This would normally require some level of 124 
formal health technology assessment (HTA). 125 
 126 
3.3.2 Translational Adoption of Regenerative Medicines 127 
Participants’ responses relating to the translation of RM therapies in ophthalmology could 128 
be classified into 5 core recurrent themes of importance. These were: trial funding; design 129 
and execution of RM trials; trial support and infrastructure; the trial approval process and 130 
clinicians’ positions and attitude to translation (Figure 2). Factors relating to manufacturing 131 
challenges and national research priorities were also mentioned multiple times although 132 
with significantly lower frequency (Figure 2A).  133 
Themes of clinician position and attitudes and trial funding were viewed as important by a 134 
number of respondents although there were mixed opinions as to whether these were likely 135 
to be barriers or enablers to translation of RM therapies. Key differences between the 136 
responses of UK and Canadian participants were seen in the areas of trial support and 137 
infrastructure and most starkly in the trial approval process. In Canada the research ethics 138 
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board (REB) review process was a recurrent point of discontent for participants. Seven 139 
respondents detailed an extremely slow, highly bureaucratic process which had been a 140 
cause of concern for many years.  141 
“I mean in Canada these things [REB] are very very very very slow.”CAR5  142 
Seven Canadian respondents in total gave accounts of a process that slowed processes 143 
significantly and absorbed applicant’s time. Three  thought that this may act as a deterrent 144 
for clinicians to engage in clinical trials, with one detailing specific issues in a multi-national 145 
study that they were part of, commenting “by the time our centre got ethics approval for the 146 
trial, the study was nearly two thirds complete” CAR9  147 
It was suggested by two participants that the slow ethics review process in Canada was due 148 
to an overtly bureaucratic system, tied down by a requirement for perfect submissions, but 149 
also more recently in an expanding scope of the ethics boards. It appeared to many that 150 
these processes do not have statutory timescales in place for review; neither do they have 151 
the capacity for obtaining a single approval for a multi centred trial. 152 
In contrast only one UK participant detailed issues with the clinical trial application and the 153 
associated review process; although for this particular respondent it was a cause of 154 
frustration detailing several examples of situations where this has been “rate-limiting”UKR4 in 155 
translating RM therapies. In the UK, the process for ethics approval for clinical trials has 156 
changed in recent years [23]. Through a positive collaboration between the ethics review 157 
boards across four different approval regulators, health services research in the UK is now 158 
upheld with a single UK-wide ethical opinion. Whilst these changes were only explicitly 159 
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noted by one participant, it is possible that such changes have made trial approval in the UK 160 
more favourable for research-minded clinicians.  161 
 162 
Trial support and infrastructure was another area in which multiple stakeholders disagreed 163 
with one another. Although more UK respondents than Canadian perceived it to be an 164 
important factor in late stage translation of RM therapies, the responses were more evenly 165 
split with nearly as many positive accounts of the UK’s clinical trial infrastructure as there 166 
were negative (Figure 2B). Many comments and anecdotes revolved around the impact of 167 
the investment of the UK’s National Institute for Health Research (NIHR) into infrastructure 168 
and clinical trial partnerships. 169 
“When I look around me, in the last five years there has been a massive increase in 170 
what the NIHR has funded, and the amount the NIHR is contributing to translation 171 
and applied clinical research”UKR5 172 
A weakness in translational science has long been a problem for those working in the area of 173 
health sciences and technology in the UK. Highlighted as a priority area in the Cooksey 174 
report 2006 [24], two gaps were identified in health services research, the first in the 175 
translation of basic and clinical research into ideas and products; and the second relating to 176 
translating those ideas and products into clinical practice. Over the last 7 years the UK 177 
government has increased funding and made organisational installations in an attempt to 178 
bridge these gaps in translation [25,26]. The authors hypothesise that UK investment into 179 
clinical trial research infrastructure in the form of the NIHR Office for Clinical Research 180 
Infrastructure (NOCRI) may have some part to play in the more positive reception to trial 181 
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support and infrastructure from UK clinicians. This support has aimed to reduce the risk of 182 
running clinical trials in the UK, with various shared funding streams to help industry and 183 
academics operate expensive, complex and resource hungry trials [26]. 184 
Another area of key importance was that of trial funding, and funding streams for 185 
translational science. Five Canadian participants described favourable translational funding 186 
programmes. Canadian clinicians have in certain cases been allowed to indirectly access US 187 
NIH funding as well as Canadian Institute for Health Research (CIHR) funding which has 188 
offered a larger funding pool for this translational research.  189 
The complexity of RM trial design and execution was recognised by 12 participants in both 190 
the UK and Canada. Issues such as poorly understood patient heterogeneity and unsuitable 191 
clinical endpoint measures being described.  192 
“…you need to make sure that whatever you try you will be able to measure the 193 
response, and it sounds like a trivial detail, but the FDA accepted outcome measure is 194 
visual acuity better than 3 lines on the vision chart. That is not reasonable in the 195 
types of diseases that we are looking at. I think each condition and each stage should 196 
have their own outcome measures”.CAR6  197 
 198 
Whilst trial support and infrastructure and trial funding for clinical translation of RM was 199 
viewed by many as a barrier, it is important to note that participants from Moorfields Eye 200 
Hospital (UK) considered many of these systems to be adequate to support the current need 201 
for clinical development of these complex therapies. These participants in general, gave 202 
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more positive responses to questioning concerning translation of RM therapies than those 203 
in other centres.  204 
 205 
Moorfields eye hospital was designated as one of 12 NIHR biomedical research centres in 206 
2011, with a government investment of over £25 million to drive translational research [33]. 207 
The hospital itself is known worldwide, and is undoubtedly the most widely recognised 208 
centre for ophthalmology in the UK. Moorfields Eye Hospital was considered by two 209 
Canadian participants to give the UK a competitive advantage, in terms of its appeal to 210 
industry and the national research output in ophthalmology. However there was a shared 211 
viewpoint from three UK participants that it can sometimes be difficult to compete for both 212 
private and public grant funding opportunities in ophthalmology given the presence of 213 
Moorfields, hinting at the concentration of research taking place there. There was a more 214 
even spread of investment in Canada with multiple centres of excellence although each 215 
province was perceived to have some centres which excelled in biomedical research and 216 
translation. 217 
 218 
Throughout the PCI two key cell-therapies were mentioned time and time again. These were 219 
limbal epithelial stem cell transplantation (LESCT) for limbal epithelial stem cell deficiency 220 
(LESCD) [23], and retinal pigment epithelial (RPE) transplantation for macular degeneration 221 
and Stargardt’s [17]. 5 examples of RM trials involving these therapies were accounted for in 222 
the UK and Canada collectively in the PCI, importantly four of these in the UK (Table 2). 223 
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3.3.3 Early Use of Regenerative Medicines 224 
 225 
The term early use has been used to refer to the phase of clinical engagement in which the 226 
decision to adopt is likely to be based on lower quality clinical evidence. Typically low 227 
numbers of patients will be involved, and the therapy will not have reached a suitable point 228 
in its development to be scrutinised through a formal health technology assessment. The 229 
core themes emerging from discussion around the early use of RM therapies were: 230 
regulatory challenges; the influence of private healthcare; institutional management; 231 
bureaucracy involved in delivering novel therapies; and the changes to infrastructure or 232 
systems to allow therapies such as RM to be used (Figure 3). Ideas likely to be product 233 
specific such as cost, patient volume and risk versus benefit decisions were also raised 234 
throughout the interviews (Figure 3A). 235 
 236 
It is important to note that throughout this study the assumption has been made that the 237 
regulatory stakeholders had been satisfied by product developers. While individual clinicians 238 
may have links with the regulators, there is likely to be limited interaction between the 239 
broader clinical stakeholder group and regulatory stakeholders. Consequently regulation has 240 
not been discussed in detail here although some of the important points captured on this 241 
area from the interview process have been presented. 242 
In general, respondents in both the UK and Canada appeared to have similar perspectives 243 
on their regulatory environment for RM. Most comments on the pace of the regulatory 244 
process in Canada were largely tied to experiences outside of RM.  However one participant 245 
drew reference to the recent approval of the mesenchymal stem cell product Prochymal®. 246 
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Health Canada were the first regulator in the world to approve the therapy, albeit through a 247 
conditional approval (notice of compliance) based on further trials. Important in this process 248 
was that the Canadian regulators allowed a subset of patients to be reviewed individually. 249 
This example of facilitative regulation of an important RM therapy although not in 250 
ophthalmology, represents a critical component of the Canadian RM adoption landscape, 251 
and is likely to be attractive to other industry stakeholders looking to enter single-payer 252 
markets. 253 
 254 
Giving patients early access to therapies can be possible outside of the research setting 255 
assuming that the therapy has been approved by the relevant authorities and that 256 
authorisation can be secured from clinical management. The authors see early access 257 
mechanisms such as “hospital exemption” and “specials” schemes in the UK to offer 258 
accelerated routes to the patient and facilitate RM therapies availability in the UK [22]. In 259 
addition, the experience gained through their use can often be used in formal development.  260 
 261 
Factors relating to local organisation, like attitudes of institutional management, 262 
bureaucracy and flexibility of infrastructure and services to accommodate the early use of 263 
new therapies were all mentioned more frequently by UK participants than those from 264 
Canada. Several accounts from UK participants detailed complex and often unclear 265 
processes involving numerous departments each with individual processes  266 
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“The application form is very long and tedious – they [local management] require a 267 
lot of information and it is a deterrent for many clinicians. Clinicians really don’t have 268 
the time normally.”UKR1 269 
 270 
Related to this, more UK responses described difficulties in installing infrastructure to 271 
accommodate the early or low level use of RM. Issues included the need for clean rooms, 272 
skilled basic scientists, immunology support and intensive patient monitoring. In certain 273 
cases these requirements were seen by UK participants as being prohibitive and unlikely to 274 
be cost effective for the small patient numbers.  275 
A supportive management structure was also perceived as a crucial for early use of such 276 
novel therapies by both Canadian and UK participants. Three Canadian participants were 277 
extremely pleased with their institutional management processes and accounted for two 278 
examples of well designed, helpful programs to drive innovation in surgery. One participant 279 
from Sick Kids hospital in Toronto described in-house processes to try to drive innovation. 280 
One offering was that of a small grant competition where regular prizes of $10,000 are 281 
granted for proposals relating to testing novel unconventional hypotheses with new 282 
medicines. Such a programme undoubtedly shows the intent of management to foster 283 
innovation and adoption within their organisation. 284 
The effect of the Canadian private market that exists in Canada was perceived to play a far 285 
more important role relative to that in the UK. Many Canadian ophthalmologists appeared 286 
to think that approved therapies that were yet to receive codes for reimbursement could be 287 
delivered and charged directly to the patient, as an alternative route to offering patients 288 
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access to novel treatments. The potential patient pool is of course limited to those patients 289 
who can afford such therapies, but may be an important market access mechanism for a 290 
limited number of therapies nonetheless. Private insurance companies were perceived to 291 
have a similar outlook in both the UK and Canada employing a high evidence threshold for 292 
reimbursement. As a consequence it was unclear to many participants as to whether there 293 
would be early reimbursement mechanisms with private insurers for RM Therapies.  294 
 295 
3.3.4 System-wide Adoption of Regenerative Medicines 296 
 297 
After building conclusive evidence of a therapy’s safety, efficacy and cost–effectiveness, 298 
therapies such as RMs must overcome the hurdle of securing reimbursement, and gaining 299 
system-wide adoption. Ophthalmologists understood this phase of adoption to be the 300 
ultimate barrier to a therapy’s success. The extent to which diffusion or system adoption 301 
can occur is predicated on the patient volume, clinical need and the delivery models in place 302 
for the therapy. Multiple clinicians perceived that it was likely that RMs in ophthalmology 303 
would be confined to specialist centres with suitable infrastructure and resources to deal 304 
with delivery. The reported themes relevant to system-wide adoption included  305 
• Local Management, such as management attitudes, local budget constraints, overall 306 
health of the local institutions finances and its freedom to reallocate resource 307 
• Regional Management, such as policy setting and links to political agenda and 308 
government priorities 309 
• Health Technology Appraisal, covering issues with the UK’s National Institute for 310 
Clinical Excellence (NICE) review process and clinical guidance as well as the less 311 
centralised Canadian economic evaluation procedures 312 
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• Reimbursement systems including coding and fee tariffs where appropriate  and 313 
• Commissioning processes 314 
There are distinct differences in the way that that decision makers were organized at the 315 
local regional and national level in the UK and Canada (Figure 4A). In the UK pricing and 316 
reimbursement (P & R) and health technology assessments (HTA) are carried out at a 317 
national level. Regional bodies in the UK, namely clinical commissioning groups (CCGs) 318 
would then be concerned with regional budgets and access to medicines. At the local level 319 
issues such as service design, local budget management and infrastructure requirements are 320 
dealt with. In Canada, each of the 10 provinces has its own governmental control over the 321 
management and allocation healthcare resources. Whilst ultimately the provinces are still 322 
funded from National government transfers derived from taxation, each provincial 323 
healthcare system is autonomous and sets its own healthcare priorities. As a consequence, 324 
system-level reimbursement and even technology appraisals will largely be done at a sub-325 
national level in Canada. 326 
Large variations in the way healthcare adoption was managed and implemented appeared 327 
to be a theme on which both UK and Canadian participants agreed. Whilst such 328 
fragmentation may be expected from the Canadian system, made up of independent 329 
provincial ministries governing healthcare, the fragmentation and regional and local 330 
differences in operations in the NHS was perhaps less expected.  331 
The regional management variations in healthcare were identified by 7 UK participants, 332 
underlining the complex and heterogeneous system of healthcare in the NHS. Currently, the 333 
allocation of 70% of the healthcare budget allocated to 211 CCG’s, each responsible for a 334 
geographic region [27].  Each CCG purchases products and services for long-term conditions 335 
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and common diseases. Therapies targeting rarer diseases involving fewer patients, and 336 
often higher costs are likely to be supported by specialist services commissioning. If 337 
successful for some therapies this may potentially offer a single market-access gatekeeper 338 
albeit in the first instance for low volume therapies. 339 
Organizational inertia was a source of frustration for many respondents working in the NHS 340 
with culture and fragmentation given as potential causes. Four UK participants felt that the 341 
NHS was particularly unresponsive, and slow to progress in many aspects of care including 342 
the uptake of new healthcare technologies.  343 
“There is a traditional way of working [in the NHS] and anything that is going to 344 
change the way the system is working can be quite difficult to implement. Even the 345 
smallest change to practice can take a long time to come through even when it’s 346 
clearly beneficial to the patient.”UKR8 347 
No participants in any of the three Canadian provinces sampled, suggested that 348 
responsiveness of their provincial health organisations had been an issue. 349 
The biggest differences in responses between the UK and Canada were seen in themes 350 
relating to HTA processes, reimbursement systems and local management issues. 10 out of 351 
11 UK participants recognised the importance of NICE’s role in the adoption of new 352 
therapies.  However more were of the opinion that NICE’s current capacity, methodologies 353 
and practices may not favour RM therapies. Even outside the area of RM, several clinicians 354 
recalled instances where slow NICE review had delayed the adoption of approved therapies. 355 
 “….it [Eyelea®] was licensed throughout Europe for diabetic macular oedema and 356 
retinal vein occlusion. I can’t remember when it was available, I think about 2 years 357 
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ago. Now it’s only actually this year [2013] that NICE has approved its use for those 358 
indications.”UKR8 359 
Only 3 participants could detail processes of HTA or economic evaluation in Canada. One 360 
HTA agency that had dealt with RM therapies in the past was the Ontario Health Technology 361 
Assessment Centre (OHTAC), a provincially owned HTA agency. A structured literature 362 
search for HTA of RM in both the UK and Canada identified 4 published HTAs both either 363 
reviewed by NICE or by OHTAC (Table 3). Interestingly the two HTA bodies have disagreed 364 
on two interventions’ cases for adoption. In the use of allogeneic LESCT, both NICE and 365 
OHTAC appeared to disagree as to whether this treatment should be funded. NICE’s 366 
assessment reported that there was not enough evidence with respect to the safety and 367 
effectiveness of LESCT for the treatment to be offered routinely, but that in cases of a 368 
medical necessity special arrangements could be made to offer the treatment [28].  In 369 
contrast, OHTAC recommended the treatment for use stating that whilst the evidence to 370 
support LESCT is weak, it was considered unlikely given the rarity of the condition, that 371 
more robust evidence will be available [29]. The authors hypothesise that this more 372 
permissive assessment of LESCT by OHTAC, represents an acknowledgement of the difficulty 373 
in running trials with RM therapies in rare diseases, and demonstrates a greater flexibility in 374 
terms of HTA. Differences in assessment criteria were also apparent in the two agencies 375 
assessments of Islet cell transplantation for type 1 diabetes. It appeared that the 376 
approaches taken by the two agencies in determining whether each RM therapy 377 
represented value-for-money were very different, perhaps due to varied interpretations of 378 
clinical evidence, and different thresholds for acceptable effectiveness. 379 
 380 
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Table 3 Published HTA decisions of cell therapies in the UK and Canada 381 
Therapy 
 
NICE Decision OHTAC Decision 
Autologous limbal cell transplant for limbal cell 
deficiency  
--- Positive [29] 
Autologous limbal cell transplant for limbal 
pterygium 
--- Negative [29] 
Allogeneic limbal cell transplant for limbal cell 
deficiency  
Negative [28] Positive [29] 
Islet cell transplantation for type I diabetes  Positive [30,31] Negative [32] 
 382 
Canadian participant’s viewed the centralised and highly developed economic evaluations of 383 
NICE as more effective at rationing healthcare, and potentially having a well-defined role in 384 
the process. Interestingly only three participants could detail processes of health technology 385 
appraisal or economic evaluation in Canada. In discussions with UK participants the role of 386 
NICE was ultimately central to most responses on system-wide adoption. Whilst for many it 387 
was unclear whether RMs targeting some of the rarer conditions would warrant NICE 388 
review, its role in adoption was seen as critical. Within scarce NHS resources, it was 389 
appreciated that payers need new therapies such as RM to provide value for money. Two 390 
UK participants recognised that RM therapies are likely to have very high initial prices but 391 
these could drop as expertise and tools for manufacturing and distribution are developed.  392 
The initial costs of RM therapies are likely to be a critical factor in their adoption. A report 393 
from the UK government recently stated that NICE’s assessments should include 394 
consideration that early investment in this area could help bring further treatments to the 395 
market which may have impact in providing savings in healthcare and in  increased 396 
investment in the UK [33]. 397 
One UK ophthalmologist recognised that RM therapies for rarer diseases may be unsuitable 398 
for NICE appraisal and may well be better serviced by specialised services commissioning.  399 
 Regenerative Medicine 
 
“I think specialist services commissioning is potentially a route to allowing some level 400 
of adoption or some level of evaluation, all be it in a constrained fashion.  But during 401 
that time you’ve got the opportunity to actually feed the product into the NHS, start 402 
to test it, put it through some real world evaluation and see how it works in 403 
practice.”UKR1 404 
NHS Specialised services were also recognised as an important component of adoption in 405 
the 2013 UK government response to the recommendations made in the recent House of 406 
Lords Science and Technology Select Committee report on RM. Herein it was noted that a 407 
new approach to commissioning services that are currently lacking in evidence would be 408 
adopted. The process termed commissioning through evaluation (CtE) would look at 409 
services deficient of both clinical and/or cost effectiveness evidence which are thus 410 
unsuitable for routine commissioning [33]. 411 
When respondents in both the UK and Canada were asked to describe the local and regional 412 
decision making processes involved in adopting a new therapy a wide range of responses 413 
were recorded. Local and regional processes for uptake of a particular therapy appeared to 414 
be varied between different regions. Issues relating to local management in the UK were a 415 
cause of concern to several respondents in the UK.  Factors including management attitude, 416 
patient volume, infrastructure and precedence for the use of similar therapies were all seen 417 
to affect the institutional uptake of new therapies.  418 
Whilst the NHS and Canadian health systems share their first principles and some aspects of 419 
healthcare organisation (Table 4), the systems have developed significantly different 420 
processes for dealing with the uptake of RM therapies (Table 5). Whilst both offer some 421 
form of evidence-based healthcare, the two are still guided by value for money, and 422 
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differences in the way that value for money is assessed between the two nations (Table 3) 423 
will be an important area for future exploration. 424 
3.3.5 Ophthalmology as a Target Clinical Area 425 
 426 
An important feature of this work was the characteristics of the specific clinical group that was 427 
interviewed. A key question to ask was “are there any specific characteristics of ophthalmologists or 428 
ophthalmology in general that may impact on any of the three areas investigated. Ophthalmologists 429 
perceived themselves to be quieter, less aggressive and on the whole easier to manage than other 430 
surgical specialisms (i.e. cardiac surgeons). In addition one participant thought that ophthalmology 431 
departments had historically been inward looking located in isolated centres away from other 432 
clinical departments.  433 
Many respondents were keen to describe how ophthalmology as a clinical area could offer many 434 
benefits as a target site for RM therapies. Such benefits included: 435 
• Measureable outcomes:  “…ophthalmology is much more amenable to clinical trials and the 436 
outcomes are directly measurable”CAR8. “We are spoilt in ophthalmology by being able to 437 
readily assess structure and function…” CAR6 438 
• Isolated organ for targeted therapeutics: “We’re really interested in RM in the eye because 439 
you can affect the phenotype of cells in the eye locally without affecting it systemically. You 440 
could only do this in ophthalmology…” CAR4 441 
• Easy access to test neurological therapeutics: “…for a neurological disease, I think the eye is 442 
the best test site in humans.  It will be easy; surgery is very trivial compared to anywhere else 443 
in the brain.  We know what kind of cell we need to fix.  In the brain it is not always 444 
obvious.”CAR11 445 
 446 
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The idea that technology and therapies in ophthalmology may evolve quicker than other surgical 447 
based clinical areas was noted by four participants.  448 
“I think in general ophthalmologists adopt very quickly because the field changes very 449 
quickly. To at least stay at the standard of care, you have to.”CAR5  450 
With the exception ocular cancers, the majority of indications treated by ophthalmologists are non-451 
fatal, and thus are seen by policy makers as a lower priority, than for instance cardiovascular 452 
medicine or cancer care. 453 
 454 
3.5 Conclusions 455 
The aim of this work was to identify the factors likely to determine adoption of RM therapies in 456 
ophthalmology in the UK and Canada. Factors which appeared to be similar between the UK and the 457 
comparator, Canada included evidence-based decision making; bureaucracy, and regional 458 
management issues. However there were several differences that emerged from the samples that 459 
will no doubt impact on adoption of future RM therapies. 460 
Favourable processes surrounding clinical research infrastructure, funding and ethics approval 461 
appear to have contributed to making the UK a more favourable setup than Canada for RM 462 
translation in ophthalmology in recent years. However when it comes to early use and system-wide 463 
adoption of RM therapies, the NHS was perceived to find uptake harder to manage, with local 464 
management and institutional infrastructure being perceived far more of a barrier than in Canada. 465 
Examples of excellent management behaviours and setup in Canadian ophthalmology departments 466 
were an area which NHS management would do well to learn from. Several participants giving 467 
examples of forward thinking and innovative programmes to drive adoption and ensure Canadian 468 
clinicians bridged the gap between translation and adoption of such therapies. 469 
 Regenerative Medicine 
 
Each healthcare system is associated with national assets which could be appealing to therapy 470 
developers working in this space. Health Canada has in recent years proven itself to be a forward 471 
thinking regulator willing to look at RM therapies as exceptional technologies. In addition local 472 
healthcare providers appeared more supportive of earlier use of therapies and isolated cases uptake 473 
of RM into clinical programs. Internally in the UK, the investment and growth of Moorfields Eye 474 
Hospital whilst seen by some UK insiders as a sink for UK funding in ophthalmology, has undoubtedly 475 
given the UK a competitive advantage in basic and clinical research in RM. 476 
As markets, single-payer healthcare systems do have some similar characteristics (Box 1) and they 477 
could have the potential to offer a “one-stop shop” for therapy developers to tackle. Ideologically, a 478 
single value system, with a uniform willingness to pay, is a far simpler proposition than that of the 479 
numerous evaluation procedures in insurance based healthcare systems. Arguably the biggest 480 
challenge in building a sustainable RM industry sector in both the UK and Canada will be in 481 
persuading decision makers to adopt truly innovative therapies which in the short term may not be 482 
cost effective, but that could give rise to a range of therapeutics which change the way we deliver 483 
healthcare. 484 
 485 
3.6 Future Perspective 486 
 487 
At current there are few authorized RM products and even fewer which have secured adoption and 488 
reimbursement. However, the resources currently being invested in RM research and development 489 
will in the near future undoubtedly yield a number of therapies, some of which may offer long-term 490 
cost savings. Ensuring there are suitable evaluation pathways, well developed routes to 491 
reimbursement, and that healthcare providers are prepared will be critical in providing a suitable 492 
adoption environment for RM. If addressed early the UK and Canada could demonstrate themselves 493 
as extremely attractive early markets for RM, to the benefit of both healthcare and inward industry 494 
investment.  495 
 Regenerative Medicine 
 
 496 
4. Executive Summary 497 
Translation 498 
• The UK appears to offer a favourable environment for translation of RM therapies, providing 499 
a supportive environment through investment into infrastructure.  500 
• The Canadian research ethics process is currently a rate limiting component of the clinical 501 
trial process 502 
Early Use  503 
• Canadian regulators Health Canada have demonstrated a desire to move RM forward, being 504 
first to approve a number of RM therapies. 505 
• Healthcare provider management in Canada appears to be driving innovation and adoption 506 
of new ways of working. 507 
• The NHS’s specialist commissioning group are developing new routes for adoption of 508 
therapies targeting low patient numbers (CtE), likely to be relevant for RM therapies. 509 
 510 
System-Wide Adoption 511 
• The NHS is still recognised as unresponsive, and has been slow to uptake new medicines, 512 
especially struggling with disruptive innovations. 513 
• Short term commissioning behaviours and silo budgets in the NHS could make it challenging 514 
to demonstrate to decision makers the real value of potentially “curative” treatments. 515 
• NICE is internationally recognised as a leader in clinical guidance and technology 516 
assessment. Canada’s multiple technology assessment processes are less coordinated and 517 
significantly more complex to navigate. 518 
 519 
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Figures 612 
 613 
 Table 1 Sample size and response rates for the UK and Canadian sample 614 
 Invited Responded Response Rate 
UK 34 11 32% 
Canada 44 11 27% 
 615 
 616 
Figure 1 Three phases of potential clinical adoption: Translation, Early use and System-wide 617 
adoption. 618 
 619 
 620 
Figure 2 Recurrent themes derived from PCI, relating specifically to issues in the translation stage 621 
of clinical development. A) Pie chart representing relative contribution of themes as a percentage 622 
of total coded passages combining UK and Canadian responses. B) Bar chart representing 623 
grounded values for 5 key themes as enablers or barriers or barriers to adoption in the UK and 624 
Canada.   625 
 626 
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 627 
Table 2 Cell therapy trials ongoing in ophthalmology in the UK and Canada 628 
Location Sponsor Trial Indication Start Status 
UK, 
Newcastle  
Newcastle 
University 
Autologous cultured human limbal 
epithelium for limbal stem cell 
deficiency (ophthalmology) 
Limbal stem cell  
deficiency 
2012 Phase II 
UK, 
Edinburgh 
Edinburgh  
University, 
Scottish  
National Blood  
Transfusion 
Service 
Corneal stem cells (allogeneic 
limbal epithelial stem cells on 
amniotic membrane) 
Limbal stem cell  
deficiency 
2011 Phase I 
/II 
UK,  
London  
Edinburgh 
Advanced Cell 
Technologies 
Retinal pigment epithelial cell 
replacement for Stargardt's 
disease 
Stargardt's 
disease 
2011 Phase I 
/II 
UK,  
London 
Pfizer A Study Of Implantation Of Human 
Embryonic Stem Cell Derived 
Retinal Pigment Epithelium In 
Subjects With Acute Wet Age 
Related Macular Degeneration 
And Recent Rapid Vision Decline 
Acute  wet Age 
related Macular 
Degeneration 
2014 Phase I 
Canada, 
Quebec 
CHU de Québec Autologous Cultured Corneal 
Epithelium (CECA) for the 
Treatment of Limbal Stem 
Cell Deficiency 
 
Limbal stem cell  
deficiency 
2012 Phase I 
/II 
 629 
Figure 3 Recurrent themes derived from PCI, relating specifically to issues in the early use of RM 630 
therapies. A) Pie chart representing relative contribution of themes as a percentage of total coded 631 
passages combining UK and Canadian responses. B) Bar chart representing grounded values for 5 632 
key themes as enablers or barriers or barriers to adoption in the UK and Canada.     633 
 634 
 635 
 636 
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Figure 4 A) Schematic of differences in in health system organisation between Canada and UK -637 
P&R: Pricing and Reimbursement; HTA: Health Technology Assessment. B and C) Recurrent themes 638 
derived from PCI, relating specifically to issues in the system-wide adoption of RM therapies. A) Pie 639 
chart representing relative contribution of themes as a percentage of total coded passages 640 
combining UK and Canadian responses. B) Bar chart representing grounded values for 5 key 641 
themes as enablers or barriers or barriers to adoption in the UK and Canada.    642 
 643 
 644 
 645 
 646 
 647 
 648 
 649 
 650 
 651 
 Regenerative Medicine 
 
Table 4 Comparison of Healthcare in UK and Canada 652 
UK Canada 
Universal Health Care Universal Health Care 
Publically funded  Publically funded 
Publically delivered Privately  delivered 
212 CCGs, directly answerable to Dept. of Health 10 autonomous Provincial Ministries 
Physicians salaried  Physicians paid “fee for service” - capped 
Increasing level of patient choice but referral based on  
physician availability 
Healthcare is Semi-competitive for high volume, well 
reimbursed procedures (cataracts etc.) 
NICE commissions HTA HTA carried out at national, provincial and local levels 
Patented  drug prices agreed through designated pricing 
groups (PPRS) 
High prices for patented pharmaceuticals  varying from 
province to province 
9.6% GDP spent on healthcare annually 11.9% GDP spent on healthcare annually 
£2170 spent on healthcare per capita £3240  spent on healthcare per capita 
 653 
 654 
Table 5: Overview of key comparative points emerging from interview data 655 
Phase UK Canada 
Translation ↑ Single national ethics approval  ↓Prohibitively slow ethics review process 
 ↑ Significant investment into trial 
infrastructure through NIHR 
↔ Limited support and funding for 
translational research 
Early Use  ↔ Regulated as ATMPs  under EMA ↑ Forward looking regulator, willing to look 
at RMs as exceptional therapies 
 ↓ Management attitudes a barrier in some 
institutions 
↑ Examples of outstanding leadership in 
institutional management 
 ↑ Specialist commissioning routes  being 
developed for RM. 
↔ RM will fit into normal commissioning 
pathways 
System-Wide 
Adoption 
↓ Unresponsive organisation slow to instil 
changes  
↑ Several small responsive healthcare 
organisations with well-defined patient needs 
 ↓ At current short term commissioning 
behaviours, and “silo budgets” 
↔ Signs of movement towards long term 
“continuity of care” models  
 ↑ Single national assessment of cost 
effectiveness -internationally referenced 
↔ Provincial variations with highly variable 
HTA processes 
 656 
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 657 
Box 1 Common characteristics of single payer healthcare systems (derived from UK and Canadian 658 
interviews) 659 
Characteristics of Single Payer HealthCare Markets 
• Driven by cost-effectiveness 
• Decisions made on quantity and quality of evidence 
• Systems are able to offer an economic threshold for life  
• More rational, more consistent discussions over pricing 
• Opaque budget approval processes, widely varied by region 
• Less likely to give reimbursement for marginal improvements,  
• Potential to offer continuity of care  
• Clinical trials may benefit from access to entire patient populations  
 660 
